Table 1.
Demographic and clinical data of patients with chronic rhinosinusitis with (CRSwNP) or without nasal polyps (CRSsNP) and healthy subjects in included studies.
| Study | Pop (n) | Males (%) | Age (Years) | Smoking (%) | Atopy (%) | Asthma (%) | Intranasal CCS (%) | Lund–Mackay CT Score | SNOT-22 Score | FEV1 (% Predicted) | FEV1/FVC | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRSwNP vs. HEALTHY | ||||||||||||
| Arnal 1999—No allergy [28] | Pts | 20 | 65.0 | 48.0 | 15.0 | 0 | 10.0 | 55.0 | - | - | - | - |
| Controls | 42 | 52.4 | 42.0 | 0 | 0 | N/A | N/A | N/A | N/A | - | - | |
| Arnal 1999—Allergy [28] | Pts | 7 | 71.4 | 42.0 | 15.0 | 100 | 71.4 | 14.3 | - | - | - | - |
| Controls | 42 | 52.4 | 42.0 | 0 | 0 | N/A | N/A | N/A | N/A | - | - | |
| Asano 2018 [29] | Pts | 11 | - | - | 0 | 100 | 100 | 0 | - | - | - | - |
| Controls | 10 | - | - | 0 | 0 | N/A | N/A | N/A | N/A | - | - | |
| Bommarito 2008 [30] | Pts | 30 | 63.3 | 52.0 | 0 | 57.0 | - | 0 | 13.5 | - | - | - |
| Controls | 29 | 31.0 | 39.0 | 0 | 55.0 | N/A | N/A | N/A | N/A | - | - | |
| Frendø 2018 [31] | Pts | 57 | 70.2 | 49.3 | - | 32.0 | 44.0 | 0 | - | - | - | - |
| Controls | 30 | 36.7 | 34.5 | - | 0 | N/A | N/A | N/A | N/A | - | - | |
| Gilian 2002 * [32] | Pts | 18 | 77.8 | - | - | - | 0 | - | - | - | - | - |
| Controls | 21 | 33.3 | - | - | - | N/A | N/A | N/A | N/A | - | - | |
| Guilemany 2009 [33] | Pts | 22 | 50.0 | 49.0 | 4.5 | - | - | - | 10.8 | - | 80.0 | 92.0 |
| Controls | 20 | 50.0 | 59.0 | 0 | - | N/A | N/A | N/A | N/A | 90.0 | 96.0 | |
| Gupta 2013 [21] | Pts | 24 | - | 54.5 | - | - | - | - | - | 28.2 | - | - |
| Controls | 11 | - | 45.7 | - | - | N/A | N/A | N/A | N/A | - | - | |
| Heffler 2014 [34] | Pts | 34 | - | - | 0 | - | 100 | 0 | 13.0 | - | - | - |
| Controls | 40 | 25.0 | 48.7 | 0 | 20.0 | N/A | N/A | N/A | N/A | 97.2 | 82.3 | |
| Jeong 2014—No allergy [16] | Pts | 30 | 53.3 | 33.4 | - | 0 | 0 | 0 | 14.6 | - | - | - |
| Controls | 30 | 50.0 | 27.3 | - | 0 | N/A | N/A | N/A | N/A | - | - | |
| Jeong 2014—Allergy [16] | Pts | 27 | 77.8 | 33.4 | - | 100 | 0 | 0 | 11.6 | - | - | - |
| Controls | 30 | 50.0 | 27.3 | - | 0 | N/A | N/A | N/A | N/A | - | - | |
| Liu 2017 [35] | Pts | 54 | 61.1 | - | 0 | 27.7 | 0 | 0 | - | - | - | - |
| Controls | 20 | 85.0 | 35.5 | 0 | 0 | N/A | N/A | N/A | N/A | - | - | |
| Noda 2012—Medical group [36] | Pts | 12 | - | 57.9 | - | - | 75.0 | 0 | 14.2 | - | - | - |
| Controls | 32 | - | 50.0 | - | - | N/A | N/A | N/A | N/A | - | - | |
| Noda 2012—Surgical group [36] | Pts | 24 | 56.2 | - | - | 58.3 | 0 | 16.9 | - | - | - | |
| Controls | 32 | - | 50.0 | - | - | N/A | N/A | N/A | N/A | - | - | |
| Torretta 2015 * [37] | Pts | 37 | - | - | - | - | - | - | - | - | - | - |
| Controls | 36 | - | - | - | - | N/A | N/A | N/A | N/A | - | - | |
| Tworek 2012 [38] | Pts | 10 | 50.0 | 38.9 | 0 | 70.0 | 0 | 0 | - | - | 89.7 | - |
| Controls | 10 | 60.0 | 41.0 | 0 | 60.0 | N/A | N/A | N/A | N/A | 92.2 | - | |
| Weschta 2008 [39] | Pts | 6 | - | - | - | - | - | 0 | - | - | - | - |
| Controls | 10 | 30.0 | 38.0 | 0 | 0 | N/A | N/A | N/A | N/A | - | - | |
| Williamson 2010 [40] | Pts | 38 | 55.3 | 52.0 | - | 57.9 | 0 | 0 | - | - | 101.1 | - |
| Controls | 41 | 46.3 | 27.0 | - | 0 | N/A | N/A | N/A | N/A | 98.4 | - | |
| CRSsNP vs. HEALTHY | ||||||||||||
| Alexandersson 2019 [27] | Pts | 12 | 33.0 | 46.0 | 0 | 33.0 | 17.0 | 67.0 | 9.7 | 50.7 | - | - |
| Controls | 12 | 42.0 | 35.0 | 0 | 50.0 | N/A | N/A | N/A | N/A | |||
| Arnal 1999 [28] | Pts | 10 | 70.0 | 47.0 | 20.0 | 0 | 10.0 | 70.0 | - | - | - | - |
| Controls | 42 | 52.4 | 42.0 | 0 | 0 | N/A | N/A | N/A | N/A | - | - | |
| Asano 2008 [29] | Pts | 13 | - | - | 0 | 100 | 100 | 0 | - | - | - | - |
| Controls | 10 | - | - | 0 | 0 | N/A | N/A | N/A | N/A | - | - | |
| Bommarito 2008 [30] | Pts | 14 | 50.0 | 42.0 | 0 | 50.0 | - | 0 | 5.7 | - | - | - |
| Controls | 29 | 31.0 | 39.0 | 0 | 55.0 | N/A | N/A | N/A | N/A | - | - | |
| Guilemany 2009 [33] | Pts | 46 | 13.0 | 56.0 | 9.0 | - | - | - | 8.4 | - | 81.0 | 92.0 |
| Controls | 20 | 50.0 | 59.0 | 0 | - | N/A | N/A | N/A | N/A | 90.0 | 96.0 | |
| Gupta 2013 [21] | Pts | 31 | - | 52.3 | - | - | - | - | - | 25.2 | - | - |
| Controls | 11 | - | 45.7 | - | - | N/A | N/A | N/A | N/A | - | - | |
| Heffler 2013 [34] | Pts | 7 | - | - | 0 | - | 100 | 0 | 3.0 | - | - | - |
| Controls | 40 | 25.0 | 48.7 | 0 | 20.0 | N/A | N/A | N/A | N/A | 97.2 | 82.3 | |
| Lindenberg 1997 [17] | Pts | 12 | 50.0 | 46.8 | 25.0 | 22.7 | - | 0 | - | - | - | - |
| Controls | 66 | 50.0 | 34.6 | 9.1 | 16.7 | N/A | N/A | N/A | N/A | - | - | |
| Liu 2017 [35] | Pts | 34 | 79.4 | - | 0 | 38.2 | 0 | 0 | - | - | - | - |
| Controls | 20 | 85.0 | 35.5 | 0 | 0 | N/A | N/A | N/A | N/A | - | - | |
| Weschta 2008 [39] | Pts | 4 | - | - | - | - | - | 0 | - | - | ||
| Controls | 10 | 30.0 | 38.0 | 0 | 0 | N/A | N/A | N/A | N/A | - | - | |
| CRSwNP vs. CRSsNP | ||||||||||||
| Arnal 1999 [28] | Pts | 20 | 65.0 | 48.0 | 15.0 | 0 | 10.0 | 55.0 | - | - | - | - |
| Controls | 10 | 70.0 | 47.0 | 20.0 | 0 | 10.0 | 70.0 | - | - | - | - | |
| Asano 2008 [29] | Pts | 11 | - | - | 0 | 100 | 100 | 0 | - | - | - | - |
| Controls | 13 | - | - | 0 | 100 | 100 | 0 | - | - | - | - | |
| Bae 2014 * [41] | Pts | 16 | - | - | - | - | - | - | - | - | - | - |
| Controls | 19 | - | - | - | - | - | - | - | - | - | - | |
| Bommarito 2008 [30] | Pts | 30 | 63.3 | 52.0 | 0 | 57.0 | - | 0 | 13.5 | - | - | - |
| Controls | 14 | 50.0 | 42.0 | 0 | 50.0 | 0 | 0 | 5,7 | - | - | - | |
| Fu 2015 [42] | Pts | 53 | 67.9 | 44.5 | 17.0 | 18.9 | 20.8 | - | 16.4 | 42.7 | - | - |
| Controls | 16 | 56.2 | 45.6 | 18.0 | 25.0 | 12.5 | - | 11.8 | 47.7 | - | - | |
| Fu 2017 [20] | Pts | 12 | 45.9 | 50.0 | 33.3 | 41.7 | 0 | - | 9.8 | 39.3 | - | - |
| Controls | 13 | 52.6 | 53.8 | 30.7 | 30.7 | 0 | - | 6.5 | 37.6 | - | - | |
| Guilemany 2009 [33] | Pts | 22 | 50.0 | 49.0 | 4.5 | - | - | - | 10.8 | - | 80.0 | 92.0 |
| Controls | 46 | 13.0 | 56.0 | 9.0 | - | - | - | 8.4 | - | 81.0 | 92.0 | |
| Gupta 2013 [21] | Pts | 24 | - | 54.5 | - | - | - | - | - | 28.2 | - | - |
| Controls | 31 | - | 52.3 | - | - | - | - | - | 25.2 | - | - | |
| Heffler 2013 [34] | Pts | 34 | - | - | 0 | - | 100 | 0 | 13.0 | - | - | - |
| Controls | 7 | - | - | 0 | - | 100 | 0 | 3.0 | - | - | - | |
| Lee 2015 [18] | Pts | 33 | - | - | - | - | - | 100 | - | - | - | - |
| Controls | 6 | - | - | - | - | 0 | 0 | - | - | - | - | |
| Liu 2017 [35] | Pts | 54 | 61.1 | - | 0 | 27.7 | 0 | 0 | - | - | - | - |
| Controls | 34 | 79.4 | - | 0 | 38.2 | 0 | 0 | - | - | - | - | |
| Ragab 2006—Medical group [43] | Pts | 16 | - | - | - | - | - | - | - | - | - | - |
| Controls | 29 | - | - | - | - | 0 | - | - | - | - | - | |
| Ragab 2006—Surgical group [43] | Pts | 19 | - | - | - | - | - | - | - | - | - | - |
| Controls | 25 | - | - | - | - | 0 | - | - | - | - | - | |
| Weschta 2008 [39] | Pts | 6 | - | - | - | - | - | 0 | - | - | - | - |
| Controls | 4 | - | - | - | - | - | 0 | - | - | - | - | |
| Yoshida 2019 [19] | Pts | 22 | - | - | - | - | - | 0 | - | - | - | - |
| Controls | 30 | - | - | - | - | - | 0 | - | - | - | - | |
Pop: population; n: number; pts: patients; CCS: corticosteroids; CT: computed tomography; SNOT-22: Sino-Nasal Outcome Test-22; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; N/A: not applicable. Continuous data are expressed as mean values, unless otherwise indicated. * Only abstract available.